Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Downgrade
Sage Therapeutics cut to Market Perform at BMO Capital on valuation » 06:56
01/22/21
01/22
06:56
01/22/21
06:56
SAGE

Sage Therapeutics

$92.45 /

+1.19 (+1.30%)

As previously reported,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SAGE Sage Therapeutics
$92.45 /

+1.19 (+1.30%)

SAGE Sage Therapeutics
$92.45 /

+1.19 (+1.30%)

05:08 Today BMO Capital
Sage Therapeutics downgraded to Market Perform from Outperform at BMO Capital
01/19/21 Wedbush
Sage Therapeutics price target raised to $98 from $83 at Wedbush
01/04/21
Sage Therapeutics downgraded to Sector Perform at RBC Capital on valuation
01/04/21 Guggenheim
Sage Therapeutics upgraded to Buy from Neutral at Guggenheim
SAGE Sage Therapeutics
$92.45 /

+1.19 (+1.30%)

SAGE Sage Therapeutics
$92.45 /

+1.19 (+1.30%)

Downgrade
Sage Therapeutics downgraded to Market Perform from Outperform at BMO Capital » 05:08
01/22/21
01/22
05:08
01/22/21
05:08
SAGE

Sage Therapeutics

$92.45 /

+1.19 (+1.30%)

BMO Capital analyst Gary…

BMO Capital analyst Gary Nachman downgraded Sage Therapeutics to Market Perform from Outperform with a $95 price target.

ShowHide Related Items >><<
SAGE Sage Therapeutics
$92.45 /

+1.19 (+1.30%)

SAGE Sage Therapeutics
$92.45 /

+1.19 (+1.30%)

01/19/21 Wedbush
Sage Therapeutics price target raised to $98 from $83 at Wedbush
01/04/21
Sage Therapeutics downgraded to Sector Perform at RBC Capital on valuation
01/04/21 Guggenheim
Sage Therapeutics upgraded to Buy from Neutral at Guggenheim
01/04/21 RBC Capital
Sage Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
SAGE Sage Therapeutics
$92.45 /

+1.19 (+1.30%)

SAGE Sage Therapeutics
$92.45 /

+1.19 (+1.30%)

Tuesday
Conference/Events
Catalyst Biosciences participates in a conference call with LifeSci Capital » 12:25
01/19/21
01/19
12:25
01/19/21
12:25
BIIB

Biogen

$279.00 /

+3.16 (+1.15%)

, CBIO

Catalyst Biosciences

$6.72 /

+0.18 (+2.75%)

Catalyst's…

Catalyst's management team provides an overview of the Company's recently introduced complement programs, as well as ongoing developments with CB 2782, a novel engineered C3 degrader partnered with Biogen, on a conference call to be held on January 19 at 1pm hosted by LifeSci Capital. Webcast Link

ShowHide Related Items >><<
CBIO Catalyst Biosciences
$6.72 /

+0.18 (+2.75%)

BIIB Biogen
$279.00 /

+3.16 (+1.15%)

BIIB Biogen
$279.00 /

+3.16 (+1.15%)

01/14/21 Truist
Truist says FDA wouldn't be discussing label if not going to approve aducanumab
01/11/21 Goldman Sachs
Eli Lilly's Alzheimer's trial data a 'positive surprise,' says Goldman Sachs
12/04/20 Mizuho
Sage Therapeutics upgraded to Buy from Neutral at Mizuho
12/01/20 Truist
Sage Therapeutics price target raised to $70 from $60 at Truist
CBIO Catalyst Biosciences
$6.72 /

+0.18 (+2.75%)

12/02/20 Raymond James
Catalyst Biosciences gets Fast Track for MarzAA, says Raymond James
05/21/20 Raymond James
Catalyst Biosciences initiated with an Outperform at Raymond James
CBIO Catalyst Biosciences
$6.72 /

+0.18 (+2.75%)

BIIB Biogen
$279.00 /

+3.16 (+1.15%)

  • 18
    Jun
  • 13
    Feb
BIIB Biogen
$279.00 /

+3.16 (+1.15%)

BIIB Biogen
$279.00 /

+3.16 (+1.15%)

BIIB Biogen
$279.00 /

+3.16 (+1.15%)

BIIB Biogen
$279.00 /

+3.16 (+1.15%)

Recommendations
Sage Therapeutics price target raised to $98 from $83 at Wedbush » 08:04
01/19/21
01/19
08:04
01/19/21
08:04
SAGE

Sage Therapeutics

$91.32 /

-5.56 (-5.74%)

Wedbush analyst Laura…

Wedbush analyst Laura Chico raised the firm's price target on Sage Therapeutics to $98 from $83 and keeps an Outperform rating on the shares. Following management's latest 2021 strategic outlook, and ahead of potential Phase 2 KINETIC data for SAGE-324 in essential tremor, the analyst is formally assigning credit for the program in her model. In terms of what to expect from the upcoming readout, Chico would look for similar magnitudes of reduction in tremor via accelerometry. On safety, the analyst looks for greater clarity around sedative effects, but would look to later studies to find strategies to offset somnolence.

ShowHide Related Items >><<
SAGE Sage Therapeutics
$91.32 /

-5.56 (-5.74%)

SAGE Sage Therapeutics
$91.32 /

-5.56 (-5.74%)

01/04/21
Sage Therapeutics downgraded to Sector Perform at RBC Capital on valuation
01/04/21 Guggenheim
Sage Therapeutics upgraded to Buy from Neutral at Guggenheim
01/04/21 RBC Capital
Sage Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
12/04/20
Fly Intel: Top five analyst upgrades
SAGE Sage Therapeutics
$91.32 /

-5.56 (-5.74%)

SAGE Sage Therapeutics
$91.32 /

-5.56 (-5.74%)

Conference/Events
Catalyst Biosciences participates in a conference call with LifeSci Capital » 04:55
01/19/21
01/19
04:55
01/19/21
04:55
BIIB

Biogen

$275.84 /

-4.51 (-1.61%)

, CBIO

Catalyst Biosciences

$6.52 /

-0.14 (-2.10%)

Catalyst's…

Catalyst's management team provides an overview of the Company's recently introduced complement programs, as well as ongoing developments with CB 2782, a novel engineered C3 degrader partnered with Biogen, on a conference call to be held on January 19 at 1pm hosted by LifeSci Capital. Webcast Link

ShowHide Related Items >><<
CBIO Catalyst Biosciences
$6.52 /

-0.14 (-2.10%)

BIIB Biogen
$275.84 /

-4.51 (-1.61%)

BIIB Biogen
$275.84 /

-4.51 (-1.61%)

01/14/21 Truist
Truist says FDA wouldn't be discussing label if not going to approve aducanumab
01/11/21 Goldman Sachs
Eli Lilly's Alzheimer's trial data a 'positive surprise,' says Goldman Sachs
12/04/20 Mizuho
Sage Therapeutics upgraded to Buy from Neutral at Mizuho
12/01/20 Truist
Sage Therapeutics price target raised to $70 from $60 at Truist
CBIO Catalyst Biosciences
$6.52 /

-0.14 (-2.10%)

12/02/20 Raymond James
Catalyst Biosciences gets Fast Track for MarzAA, says Raymond James
05/21/20 Raymond James
Catalyst Biosciences initiated with an Outperform at Raymond James
CBIO Catalyst Biosciences
$6.52 /

-0.14 (-2.10%)

BIIB Biogen
$275.84 /

-4.51 (-1.61%)

  • 18
    Jun
  • 13
    Feb
BIIB Biogen
$275.84 /

-4.51 (-1.61%)

BIIB Biogen
$275.84 /

-4.51 (-1.61%)

BIIB Biogen
$275.84 /

-4.51 (-1.61%)

BIIB Biogen
$275.84 /

-4.51 (-1.61%)

Over a week ago
Conference/Events
Catalyst Biosciences participates in a conference call with LifeSci Capital » 12:13
01/15/21
01/15
12:13
01/15/21
12:13
BIIB

Biogen

$278.68 /

-1.67 (-0.60%)

, CBIO

Catalyst Biosciences

$6.42 /

-0.24 (-3.60%)

Catalyst's…

Catalyst's management team provides an overview of the Company's recently introduced complement programs, as well as ongoing developments with CB 2782, a novel engineered C3 degrader partnered with Biogen, on a conference call to be held on January 19 at 1pm hosted by LifeSci Capital. Webcast Link

ShowHide Related Items >><<
CBIO Catalyst Biosciences
$6.42 /

-0.24 (-3.60%)

BIIB Biogen
$278.68 /

-1.67 (-0.60%)

BIIB Biogen
$278.68 /

-1.67 (-0.60%)

01/14/21 Truist
Truist says FDA wouldn't be discussing label if not going to approve aducanumab
01/11/21 Goldman Sachs
Eli Lilly's Alzheimer's trial data a 'positive surprise,' says Goldman Sachs
12/04/20 Mizuho
Sage Therapeutics upgraded to Buy from Neutral at Mizuho
12/01/20 Truist
Sage Therapeutics price target raised to $70 from $60 at Truist
CBIO Catalyst Biosciences
$6.42 /

-0.24 (-3.60%)

12/02/20 Raymond James
Catalyst Biosciences gets Fast Track for MarzAA, says Raymond James
05/21/20 Raymond James
Catalyst Biosciences initiated with an Outperform at Raymond James
CBIO Catalyst Biosciences
$6.42 /

-0.24 (-3.60%)

BIIB Biogen
$278.68 /

-1.67 (-0.60%)

  • 18
    Jun
  • 13
    Feb
BIIB Biogen
$278.68 /

-1.67 (-0.60%)

BIIB Biogen
$278.68 /

-1.67 (-0.60%)

BIIB Biogen
$278.68 /

-1.67 (-0.60%)

BIIB Biogen
$278.68 /

-1.67 (-0.60%)

Conference/Events
Alzheimer's Disease International to hold a webinar » 13:55
01/14/21
01/14
13:55
01/14/21
13:55
BIIB

Biogen

$278.62 /

+11.92 (+4.47%)

Webinar focuses on…

Webinar focuses on Biogen's data from trials investigating the efficacy and safety of aducanumab, an investigational treatment for early Alzheimer's disease, on January 14 at 2 pm. Webcast Link

ShowHide Related Items >><<
BIIB Biogen
$278.62 /

+11.92 (+4.47%)

BIIB Biogen
$278.62 /

+11.92 (+4.47%)

01/14/21 Truist
Truist says FDA wouldn't be discussing label if not going to approve aducanumab
01/11/21 Goldman Sachs
Eli Lilly's Alzheimer's trial data a 'positive surprise,' says Goldman Sachs
12/04/20 Mizuho
Sage Therapeutics upgraded to Buy from Neutral at Mizuho
12/01/20 Truist
Sage Therapeutics price target raised to $70 from $60 at Truist
BIIB Biogen
$278.62 /

+11.92 (+4.47%)

BIIB Biogen
$278.62 /

+11.92 (+4.47%)

BIIB Biogen
$278.62 /

+11.92 (+4.47%)

BIIB Biogen
$278.62 /

+11.92 (+4.47%)

BIIB Biogen
$278.62 /

+11.92 (+4.47%)

Recommendations
Truist says FDA wouldn't be discussing label if not going to approve aducanumab » 12:01
01/14/21
01/14
12:01
01/14/21
12:01
BIIB

Biogen

$272.45 /

+5.75 (+2.16%)

Following the aducanumab…

Following the aducanumab presentation at the Alzheimer's Disease International meeting, Truist analyst Robyn Karnauskas said one of her main takeaways was that the SVP and Head of the neurodegeneration development unit at Biogen, Samantha Budd Haeberlein, noted that how much imaging will be appropriate for monitoring treatment with the drug if approved is a conversation the company is having with regulators. If regulators "were not going to approve adu they likely would not be discussing label" with Biogen, argues Karnauskas, who keeps a Buy rating and $443 price target on Biogen shares.

ShowHide Related Items >><<
BIIB Biogen
$272.45 /

+5.75 (+2.16%)

BIIB Biogen
$272.45 /

+5.75 (+2.16%)

01/11/21 Goldman Sachs
Eli Lilly's Alzheimer's trial data a 'positive surprise,' says Goldman Sachs
12/04/20 Mizuho
Sage Therapeutics upgraded to Buy from Neutral at Mizuho
12/01/20 Truist
Sage Therapeutics price target raised to $70 from $60 at Truist
12/01/20 Raymond James
Sage Therapeutics downgraded to Market Perform from Outperform at Raymond James
BIIB Biogen
$272.45 /

+5.75 (+2.16%)

BIIB Biogen
$272.45 /

+5.75 (+2.16%)

BIIB Biogen
$272.45 /

+5.75 (+2.16%)

BIIB Biogen
$272.45 /

+5.75 (+2.16%)

BIIB Biogen
$272.45 /

+5.75 (+2.16%)

Conference/Events
Alzheimer's Disease International to hold a webinar » 10:05
01/14/21
01/14
10:05
01/14/21
10:05
BIIB

Biogen

$269.72 /

+3.02 (+1.13%)

Webinar focuses on…

Webinar focuses on Biogen's data from trials investigating the efficacy and safety of aducanumab, an investigational treatment for early Alzheimer's disease, on January 14 at 2 pm. Webcast Link

ShowHide Related Items >><<
BIIB Biogen
$269.72 /

+3.02 (+1.13%)

BIIB Biogen
$269.72 /

+3.02 (+1.13%)

01/11/21 Goldman Sachs
Eli Lilly's Alzheimer's trial data a 'positive surprise,' says Goldman Sachs
12/04/20 Mizuho
Sage Therapeutics upgraded to Buy from Neutral at Mizuho
12/01/20 Truist
Sage Therapeutics price target raised to $70 from $60 at Truist
12/01/20 Raymond James
Sage Therapeutics downgraded to Market Perform from Outperform at Raymond James
BIIB Biogen
$269.72 /

+3.02 (+1.13%)

BIIB Biogen
$269.72 /

+3.02 (+1.13%)

BIIB Biogen
$269.72 /

+3.02 (+1.13%)

BIIB Biogen
$269.72 /

+3.02 (+1.13%)

BIIB Biogen
$269.72 /

+3.02 (+1.13%)

Conference/Events
Biogen to host conference call » 08:57
01/14/21
01/14
08:57
01/14/21
08:57
BIIB

Biogen

$266.71 /

-0.81 (-0.30%)

Conference call to review…

Conference call to review the Aducanumab data will be held on January 14 at 9 am. Webcast Link

ShowHide Related Items >><<
BIIB Biogen
$266.71 /

-0.81 (-0.30%)

BIIB Biogen
$266.71 /

-0.81 (-0.30%)

01/11/21 Goldman Sachs
Eli Lilly's Alzheimer's trial data a 'positive surprise,' says Goldman Sachs
12/04/20 Mizuho
Sage Therapeutics upgraded to Buy from Neutral at Mizuho
12/01/20 Truist
Sage Therapeutics price target raised to $70 from $60 at Truist
12/01/20 Raymond James
Sage Therapeutics downgraded to Market Perform from Outperform at Raymond James
BIIB Biogen
$266.71 /

-0.81 (-0.30%)

BIIB Biogen
$266.71 /

-0.81 (-0.30%)

BIIB Biogen
$266.71 /

-0.81 (-0.30%)

BIIB Biogen
$266.71 /

-0.81 (-0.30%)

BIIB Biogen
$266.71 /

-0.81 (-0.30%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.